scispace - formally typeset
M

Moran Shalev-Benami

Researcher at Weizmann Institute of Science

Publications -  18
Citations -  926

Moran Shalev-Benami is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Ribosomal RNA & Biology. The author has an hindex of 9, co-authored 13 publications receiving 492 citations. Previous affiliations of Moran Shalev-Benami include Stanford University.

Papers
More filters
Journal ArticleDOI

Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex

TL;DR: The structure of the CB1-Gi signaling complex bound to the highly potent agonist MDMB-Fubinaca (FUB) is presented, which compose the structural framework to explain CB1 activation by different classes of ligands and provide insights into the G protein coupling and selectivity mechanisms adopted by the receptor.
Journal ArticleDOI

Structural Basis for Teneurin Function in Circuit-Wiring: A Toxin Motif at the Synapse.

TL;DR: The 3.1-Å cryoelectron microscopy structure of the human TEN2 extracellular region (ECR) is reported, revealing a striking similarity to bacterial Tc-toxins and highlighting the unusual structural organization of TENs giving rise to their multifarious functions.
Journal ArticleDOI

2.8-Å Cryo-EM Structure of the Large Ribosomal Subunit from the Eukaryotic Parasite Leishmania

TL;DR: The 2.8-Å resolution structure of the Leishmania donovani large ribosomal subunit (LSU) derived from a cryo-EM map is presented, further enabling the structural observation of eukaryotic rRNA modifications that play a significant role in ribosome assembly and function.
Journal ArticleDOI

Atomic resolution snapshot of Leishmania ribosome inhibition by the aminoglycoside paromomycin.

TL;DR: Thecryo-EM structure of the Leishmania ribosome in complex with paromomycin reveals the mechanism by which the drug induces its deleterious effects on the parasite and highlights unique as well as conserved elements in the PAR-binding pocket that can serve as hotspots for the development of novel therapeutics.